Literature DB >> 21404555

[Lethal cholesterol crystal embolization syndrome after operation for abdominal aortic aneurysm].

Yuji Sekine1, Tatsuya Furutake, Takayoshi Kusuhara, Kenta Ann, Daisuke Nakatsuka, Michihito Nonaka, Atsushi Iwakura, Kazuo Yamanaka.   

Abstract

A 70-year-old man underwent graft replacement for infrarenal abdominal aortic aneurysm, 50 mm in diameter. Postoperatively, he suffered from bilateral lower extremital ischemia. Although he underwent emergency embolectomy of both legs under general anesthesia, severe purplish discoloration of the distal lower extremities developed, and acute renal dysfunction occurred. He was diagnosed with cholesterol crystal embolization syndrome (CCE). We initiated intravenous steroid therapy and infused prostagrandin intraarterially and conducted low density lipoprotein (LDL) apheresis. However, his renal function did not improve and his bilateral toes became necrotic completely. Multiple organ failure rapidly worsened and he died at 38 days after surgery. CCE complicated with severe renal dysfunction is a lethal iatrogenic complication after surgery for abdominal aortic aneurysm. Because the number of CCE is likely to increase in the near future, we should study about CCE more seriously.

Entities:  

Mesh:

Year:  2011        PMID: 21404555

Source DB:  PubMed          Journal:  Kyobu Geka        ISSN: 0021-5252


  2 in total

1.  Low-density lipoprotein apheresis for corticosteroid-resistant skin lesions caused by cholesterol crystal embolism: a case report and review of the literature.

Authors:  Hiroki Kobayashi; Masanori Abe; Yusuke Murata; Takashi Maruyama; Tetsuya Furukawa; Osamu Oikawa; Kazuyoshi Okada
Journal:  J Artif Organs       Date:  2015-03-28       Impact factor: 1.731

2.  Débridement of atheroma in the proximal clamp site under hypothermic circulatory arrest for repair of abdominal aortic aneurysm with severe atherosclerosis.

Authors:  Takashi Yamauchi; Suguru Kubota; Kosei Hasegawa
Journal:  J Vasc Surg Cases Innov Tech       Date:  2017-03-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.